95% CI, 0.75 to 1.32), whereas the use of GLP-1 analogues was linked to an increased risk (6.1 vs
In a post-hoc analysis of AWARD-11, the effect of dulaglutide treatment was associated with consistent safety and efficacy patterns regardless of their renal function status at baseline, with no more gastrointestinal adverse effects nor hypoglycemic events in those subjects with lower renal function [95]
Understanding what are peptides and how they degrade helps you appreciate why proper technique preserves every microgram of active compound in your vial
Multiple studies highlight its potential applications in prevention
As of March 2025, 11 states cover GLP-1s for weight loss under their state employee health plan, nine states provide coverage under their state Medicaid program, and five states provide coverage under both programs
Results The search strategy identified 833 hits, of which 42 studies were included in the final review